Search Results

MGC Pharmaceuticals Ltd, Rebrands as Argent BioPharma in Strategic Transformation Marking a significant milestone in its evolutionary journey, MGC Pharma has officially announced its rebranding to Argent BioPharma, pending approval from its shareholders.

MGC Pharmaceuticals Ltd., announces that its proprietary product CannEpil® is now available to patients in the UK by Named Patient Request.

Portfolio Expands to Include Non-Invasive Cardiorespiratory Diagnostic Systems CAIRE Inc., a subsidiary of NGK SPARK PLUG CO., LTD., will acquire St. Paul, Minnesota-based MGC Diagnostics Holdings, Inc. MGC designs, develops, manufactures, and markets non-invasive cardiorespiratory diagnostic systems, accessories, and consumables for the detection, classification, and management of cardiorespiratory disease.

MGC Diagnostics Corporation (“MGC”), a global medical technology company dedicated to cardiorespiratory health solutions, and a portfolio company of Altus Capital Partners, Inc. (“Altus”), announced today the acquisition of Lemon Medical, GmbH.

MacroGenics, Inc. (NASDAQ: MGNX) today provided an update on the Phase 2 TAMARACK study of vobramitamab duocarmazine (vobra duo, previously known as MGC018) in patients with metastatic castration-resistant prostate cancer (mCRPC).

Konstantina Katcheves, Senior VP of Innovative Global Business Development at Teva Pharmaceuticals brings insights from the World Economic Forum to SCOPE 2025.

Japan-based Taiho Pharmaceutical has worked with Araris Biotech since 2023 developing antibody-drug conjugates for the oncology space.